Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study

BACKGROUND: To evaluate the real-world effect of the IL-12/23 inhibitor ustekinumab or of a tumour necrosis factor inhibitor (TNFi) on patient-reported outcomes (PRO) and their association with effectiveness endpoints in psoriatic arthritis (PsA) patients over 3 years. METHODS: In PsABio (NCT0262776...

Descripción completa

Detalles Bibliográficos
Autores principales: Gossec, Laure, Siebert, Stefan, Bergmans, Paul, de Vlam, Kurt, Gremese, Elisa, Joven-Ibáñez, Beatríz, Korotaeva, Tatiana V., Lavie, Frederic, Noël, Wim, Nurmohamed, Michael T., Sfikakis, Petros P., Sharaf, Mohamed, Theander, Elke, Smolen, Josef S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288720/
https://www.ncbi.nlm.nih.gov/pubmed/37353788
http://dx.doi.org/10.1186/s13075-023-03058-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288720/
https://www.ncbi.nlm.nih.gov/pubmed/37353788
http://dx.doi.org/10.1186/s13075-023-03058-y

Ejemplares similares